Ofatumumab + Physicians' Choice
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Leukaemia
Conditions
Leukaemia
Trial Timeline
Apr 14, 2011 → Apr 24, 2017
NCT ID
NCT01313689About Ofatumumab + Physicians' Choice
Ofatumumab + Physicians' Choice is a phase 3 stage product being developed by Novartis for Leukaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01313689. Target conditions include Leukaemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01313689 | Phase 3 | Completed |
Competing Products
20 competing products in Leukaemia